×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Index: Clinical Trials
index
1,719 words
KG: CLINICAL TRIALS
Contents
Clinical Trials
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (59)
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Context-Dependent CRISPR Activation in Specific Neuronal Sub
Score: 0.68
Flotillin-1 Stabilization Compounds
Score: 0.68
Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution
Score: 0.68
Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.68
Excitatory Neuron Vulnerability via SLC17A7 Downregulation
Score: 0.67
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.67
Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain A
Score: 0.67
Complement C1q Subtype Switching
Score: 0.66
Arginine Methylation Enhancement Therapy
Score: 0.65
Oligodendrocyte White Matter Vulnerability
Score: 0.65
APOE-Mediated Synaptic Lipid Raft Stabilization
Score: 0.65
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.65
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.65
Synthetic Biology Rewiring via Orthogonal Receptors
Score: 0.65
Ephrin-B2/EphB4 Axis Manipulation
Score: 0.64
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.63
Programmable Neuronal Circuit Repair via Epigenetic CRISPR
Score: 0.63
TREM2-Dependent Microglial Senescence Transition
Score: 0.62
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
← Prev
pg 2/3
Next →
Related Analyses (24)
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · completed
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · completed
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Why have numerous phase 3 clinical trials failed despite adv
neurodegeneration · completed
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 19 more
Related Experiments (30)
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel
validation · proposed · Score: 0.40
Experiment Scoring Methodology
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
Synaptic Vesicle Trafficking Dysfunction Validation in Parki
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
s:** - Test MCU overexpression specifically in layer II neur
falsification · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · completed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Iron Dyshomeostasis in MSA Pathogenesis Experiment
validation · proposed · Score: 0.40
AAV-LRRK2 Gene Therapy IND-Enabling Study Design
clinical · proposed · Score: 0.40
Show 25 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.